Call Buying Activity in AbbVie (ABBV) Targets 3% Upside in Shares Into Mid-November Ahead Various Drug Trials -Susquehanna
Tweet
Share
E-mail
Get Alerts ABBV Hot Sheet
Price: $261.07 +3.99%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.7%
Revenue Growth %: +8.8%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.7%
Revenue Growth %: +8.8%
Join SI Premium – FREE
Susquehanna option strategist Alison Edwards notes call buying in AbbVie (NYSE: ABBV) ahead of various drug trials, as investors purchased Nov 91 Calls with roughly 7,500 trading for $1.25, targeting 3% upside into mid-Nov.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Increasing unusual put volume: XLI EQT ARKG ROST WEN KOS BKLN UUP DB DJ JNJ LOW FVRR
- DOJ Probing Alleged Insider Trades That Stung Susquehanna - Bloomberg
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
Susquehanna International Group of CompaniesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
